Literature DB >> 30898324

Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support.

Dharushana Muthulingam1, Joshua Bia2, Lynn M Madden3, Scott O Farnum3, Declan T Barry4, Frederick L Altice5.   

Abstract

BACKGROUND: The opioid crisis requires rapid scale-up of evidence-based interventions to treat opioid use disorder (OUD), of which pharmacologic therapies with methadone, buprenorphine or long-acting naltrexone are most effective. With recently-developed formulations, there are unprecedented treatment options. Even when pharmacologic treatment is accessible, however, uptake remains low, suggesting individual-level barriers. Decision aids are an evidence-based strategy that may overcome these barriers. This study aims to inform such a tool by describing and rank-ordering patients' considerations when deciding whether to start medication and, if starting, choosing a medication.
METHODS: Adults with OUD (N = 81) attending an addiction treatment center or syringe exchange program completed focus groups using nominal group technique, a consensus method that generates and ranks response. The qualitative component generates a broad array of responses, followed by rank-ordering to prioritize responses. Responses to questions about starting any medications and the pros and cons of five specific medications were ranked and coded.
RESULTS: The decision to initiate pharmacologic therapy and choose among medications was influenced by six key attributes in decreasing priority: (1) benefits, (2) side effects of treatment, (3) medication delivery strategies, (4) convenience, (5) how expectations for treatment are met, and (6) how medication (especially methadone) can represents trading one addiction for another.
CONCLUSIONS: Pharmacologic properties, logistical factors, and managing expectations were important themes in decision-making for starting, choosing, and staying on medications, and to a lesser degree, negative views about medications, specifically OAT, as an addiction itself. Desire for more control over treatment persisted in all themes. This study identified specific knowledge gaps, expectations, and priorities which are important for developing a decision aid for OUD treatment relevant to the target group. Nominal group technique is an established mixed-methodology that we have applied to a new population and purpose, that of conducting needs assessment for decision aid development.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Decision science; Implementation science; Methadone; Naltrexone; Opioid use disorder; Patient preferences

Year:  2019        PMID: 30898324      PMCID: PMC6432946          DOI: 10.1016/j.jsat.2019.01.019

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  67 in total

1.  The veil of experience: do consumers prefer what they know best?

Authors:  G Salkeld; M Ryan; L Short
Journal:  Health Econ       Date:  2000-04       Impact factor: 3.046

Review 2.  Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.

Authors:  A T McLellan; D C Lewis; C P O'Brien; H D Kleber
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

3.  Detoxification as a gateway to long-term treatment: assessing two interventions.

Authors:  Mari Millery; Bhadra Paula Kleinman; Nayak L Polissar; Robert B Millman; Michael Scimeca
Journal:  J Subst Abuse Treat       Date:  2002-10

4.  Predicting treatment retention with a brief "Opinions About Methadone" scale.

Authors:  Deborah J Kayman; Marjorie F Goldstein; Sherry Deren; Andrew Rosenblum
Journal:  J Psychoactive Drugs       Date:  2006-03

5.  Developing a quality criteria framework for patient decision aids: online international Delphi consensus process.

Authors:  Glyn Elwyn; Annette O'Connor; Dawn Stacey; Robert Volk; Adrian Edwards; Angela Coulter; Richard Thomson; Alexandra Barratt; Michael Barry; Steven Bernstein; Phyllis Butow; Aileen Clarke; Vikki Entwistle; Deb Feldman-Stewart; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Nora Moumjid; Al Mulley; Cornelia Ruland; Karen Sepucha; Alan Sykes; Tim Whelan
Journal:  BMJ       Date:  2006-08-14

Review 6.  A systematic review of information in decision aids.

Authors:  Deb Feldman-Stewart; Sarah Brennenstuhl; Kathryn McIssac; Joan Austoker; Agathe Charvet; Paul Hewitson; Karen R Sepucha; Tim Whelan
Journal:  Health Expect       Date:  2007-03       Impact factor: 3.377

7.  Low bone density in patients receiving methadone maintenance treatment.

Authors:  Theresa W Kim; Daniel P Alford; Alan Malabanan; Michael F Holick; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2006-07-21       Impact factor: 4.492

8.  Conducting discrete choice experiments to inform healthcare decision making: a user's guide.

Authors:  Emily Lancsar; Jordan Louviere
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  Attitudes toward buprenorphine and methadone among opioid-dependent individuals.

Authors:  Robert P Schwartz; Sharon M Kelly; Kevin E O'Grady; Shannon Gwin Mitchell; James A Peterson; Heather Schacht Reisinger; Michael H Agar; Barry S Brown
Journal:  Am J Addict       Date:  2008 Sep-Oct

10.  Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.

Authors:  Gayle Ridge; Michael Gossop; Nicholas Lintzeris; John Witton; John Strang
Journal:  J Subst Abuse Treat       Date:  2008-11-11
View more
  12 in total

1.  Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.

Authors:  Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Emily Scherer; Lisa A Marsch
Journal:  J Subst Abuse Treat       Date:  2020-01-21

2.  Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study.

Authors:  Andrea K Finlay; Erica Morse; Matthew Stimmel; Emmeline Taylor; Christine Timko; Alex H S Harris; David Smelson; Mengfei Yu; Jessica Blue-Howells; Ingrid A Binswanger
Journal:  J Gen Intern Med       Date:  2020-06-24       Impact factor: 5.128

Review 3.  Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.

Authors:  Katherine Mackey; Stephanie Veazie; Johanna Anderson; Donald Bourne; Kim Peterson
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

4.  Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD): Rationale, methodology, and preliminary results.

Authors:  Larissa J Mooney; Jonathan Valdez; Sarah J Cousins; Caroline Yoo; Yuhui Zhu; Yih-Ing Hser
Journal:  J Subst Abuse Treat       Date:  2019-10-24

5.  Opioid Treatment Deserts: Concept development and application in a US Midwestern urban county.

Authors:  Ayaz Hyder; Jinhyung Lee; Ashley Dundon; Lauren T Southerland; David All; Gretchen Hammond; Harvey J Miller
Journal:  PLoS One       Date:  2021-05-12       Impact factor: 3.240

6.  Decisional considerations for methadone uptake in Kyrgyz prisons: The importance of understanding context and providing accurate information.

Authors:  Amanda R Liberman; Daniel J Bromberg; Lyuba Azbel; Julia Rozanova; Lynn Madden; Jaimie P Meyer; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2021-04-07

7.  Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review.

Authors:  Kirsten Marchand; Scott Beaumont; Jordan Westfall; Scott MacDonald; Scott Harrison; David C Marsh; Martin T Schechter; Eugenia Oviedo-Joekes
Journal:  Subst Abuse Treat Prev Policy       Date:  2019-09-11

8.  "It's way more than just writing a prescription": A qualitative study of preferences for integrated versus non-integrated treatment models among individuals with opioid use disorder.

Authors:  Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Patricia Cavazos-Rehg; Emily Scherer; Lisa A Marsch
Journal:  Addict Sci Clin Pract       Date:  2021-01-27

9.  Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder.

Authors:  Paul J Joudrey; Marynia Kolak; Qinyun Lin; Susan Paykin; Vidal Anguiano; Emily A Wang
Journal:  JAMA Netw Open       Date:  2022-04-01

10.  Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder.

Authors:  Alice Fiddian-Green; Aline Gubrium; Calla Harrington; Elizabeth A Evans
Journal:  Int J Environ Res Public Health       Date:  2022-07-30       Impact factor: 4.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.